Loading data for CGEM — first visit, this takes a few seconds.

Cullinan Therapeutics, Inc. (CGEM)

NasdaqGS: CGEM · Real-Time Price · USD

22.12

-0.21 (-0.94%)

At close: Sep 02, 2026, 3:59 PM

Alert

The price, the headline numbers and the latest news, in one place.

-0.94% (1D)

Bid	16.02
Market Cap	1.36B
Revenue (ttm)	n/a
Net Income (ttm)	-208M
	-0.02
	-3.11
	n/a
	-8.15
P/B (ttm)	4.42
P/S (ttm)	0.00
Earnings Date	May 14, 2021

Ask	28.23
Volume	96,554
Avg. Volume (20D)	899,484
Open	22.39
Previous Close	22.33
Day's Range	21.93 - 22.68
52-Week Range	5.68 - 23.19
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About CGEM

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 8, 2021

Employees 109

Stock Exchange NasdaqGS

Ticker Symbol CGEM

Website https://cullinantherapeutics.com

Full Company Profile

Financial Performance

In 2025, Cullinan Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -219.88M, an increase of 31.36%.

Financial Statements

Earnings Surprise

Cullinan Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.81 exceeds estimates by 0.04, with 24.30% YoY growth.

Next Earnings Release

Cullinan Therapeutics, Inc. is scheduled to release its earnings on May 14, 2021, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

3 weeks ago · BioPharma Dive

New Taiho, Cullinan data heats up lung cancer drug battle

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

3 weeks ago · Simply Wall St.

The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial

Cullinan Therapeutics reported second-quarter 2026 results with a net loss of US$53.7 million and basic loss per share of US$0.81, both lower than a year earlier, alongside six-month net loss of US$10...

1 month ago · Simply Wall St.

Cullinan Therapeutics (CGEM) Advances CLN 049 After FDA Feedback, Is The Upside Already Priced In?

Cullinan Therapeutics (CGEM) drew investor attention after receiving positive U.S. Food and Drug Administration feedback on its End of Phase 1 meeting for CLN-049 in acute myeloid leukemia. See our la...

2 months ago · Exec Edge

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clon...

2 months ago · Simply Wall St.

Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes

Earlier in June 2026, Cullinan Therapeutics reported updated Phase 1 data showing CLN-978 and velinotamig produced strong clinical responses and favorable safety in treatment-refractory rheumatoid art...

Page 1 of 2

Cullinan Therapeutics, Inc. (CGEM)